Skip to main content

Table 1 Baseline characteristics and dosimetric comparison between nCRT with or without pembrolizumab among ESCC patients

From: Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort

name

levels

Overall cohort(N = 216)

without pembrolizumab (N = 72)

with pembrolizumab (N = 144)

p

age

Mean ± SD

64.2 ± 7.6

64.3 ± 8.1

64.1 ± 7.4

0.84

sex

female

35(16.2%)

13 (18.1%)

22 (15.3%)

0.74

 

male

181(83.8%)

59 (81.9%)

122 (84.7%)

 

BMI

Mean ± SD

22.5 ± 2.8

22.4 ± 2.9

22.5 ± 2.8

0.88

T stage

T2

45(20.8%)

19(26.4%)

26(18.1%)

0.36

 

T3

165(76.4%)

51(70.8%)

114(79.2%)

 
 

T4

6(2.8%)

2(2.8%)

4(2.8%)

 

N stage

N0

4(1.9%)

0(0%)

4(2.8%)

0.47

 

N1

73(33.8%)

24(33.3%)

49(34%)

 
 

N2

92(42.6%)

30(41.7%)

62(43.1%)

 
 

N3

47(21.8%)

18(25%)

29(20.1%)

 

Tumor location

Upper

11(5.1%)

3 (4.2%)

8 (5.6%)

0.09

 

middle

125(57.9%)

35 (48.6%)

90 (62.5%)

 
 

Distal/GEJ

70(32.4%)

34 (47.2%)

46 (32.0%)

 

Stage

IIA

5 (2.3%)

0(0%)

5(3.5%)

0.21

 

IIIA

8 (3.7%)

1(1.4%)

7(4.9%)

 
 

IIIB

155 (71.8%)

53(73.6%)

102(70.8%)

 
 

IVA

48 (22.2%)

18(25%)

30(20.8%)

 

Primary tumor length (cm)

Mean ± SD

4.6 ± 2.4

4.6 ± 2.2

4.6 ± 2.5

0.91

mCPD, cGy

Mean ± SD

1026.7 ± 277.4

1031.9 ± 231.6

1024.1 ± 298.4

0.83

V5

Mean ± SD

59.2 ± 15.3

60.1 ± 15.9

58.8 ± 15.0

0.56

V10

Mean ± SD

42.8 ± 12.5

43.1 ± 12.8

42.6 ± 12.4

0.79

V20

Mean ± SD

26.3 ± 14.3

26.7 ± 18.2

26.1 ± 11.9

0.83

V30

Mean ± SD

16.0 ± 11.1

15.0 ± 10.9

16.5 ± 11.2

0.35

V40

Mean ± SD

9.3 ± 9.7

8.8 ± 9.7

9.6 ± 9.7

0.57

Mean TVB dose, cGy

Mean ± SD

1841.8 ± 510.8

1835.6 ± 474.5

1845.0 ± 529.5

0.90

TVB V5

Mean ± SD

70.8 ± 17.6

70.3 ± 17.2

71.0 ± 17.8

0.77

TVB V10

Mean ± SD

66.1 ± 16.7

66.0 ± 16.4

66.1 ± 16.9

0.94

TVB V20

Mean ± SD

55.8 ± 16.9

55.2 ± 16.4

56.1 ± 17.2

0.72

TVB V30

Mean ± SD

39.4 ± 20.4

38.1 ± 21.9

40.0 ± 19.6

0.54

TVB V40

Mean ± SD

24.1 ± 24.4

23.5 ± 25.9

24.4 ± 23.7

0.79

Mean ribs dose, cGy

Mean ± SD

720.5 ± 198.1

739.5 ± 185.8

710.9 ± 203.9

0.32

RV5

Mean ± SD

38.3 ± 10.1

39.8 ± 11.7

37.5 ± 9.1

0.15

RV10

Mean ± SD

29.7 ± 7.7

30.4 ± 8.2

29.4 ± 7.4

0.37

RV20

Mean ± SD

18.9 ± 8.1

19.0 ± 8.7

18.8 ± 7.8

0.82

RV30

Mean ± SD

11.0 ± 9.1

10.8 ± 9.6

11.1 ± 8.8

0.85

RV40

Mean ± SD

6.2 ± 9.6

5.8 ± 8.5

6.4 ± 10.0

0.65

Mean Sternum dose, cGy

Mean ± SD

1611.5 ± 637.8

1643.2 ± 670.8

1595.6 ± 622.5

0.61

SV5

Mean ± SD

85.8 ± 19.4

85.1 ± 19.5

86.2 ± 19.4

0.69

SV10

Mean ± SD

73.7 ± 25.1

73.2 ± 26.2

74.0 ± 24.6

0.83

SV20

Mean ± SD

49.0 ± 26.6

46.9 ± 26.7

50.1 ± 26.6

0.41

SV30

Mean ± SD

26.7 ± 26.9

25.1 ± 27.1

27.5 ± 26.8

0.54

SV40

Mean ± SD

14.7 ± 23.6

13.6 ± 23.5

15.2 ± 23.7

0.64

  1. Abbreviations: BMI: Body Mass Index; GEJ: gastroesophageal junction; SD: standard deviation; mCPD: mean cardiopulmonary dose; TVB: thoracic vertebrae body; RV: volume of ribs; SV: volume of sternum;
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us